Holen Sie sich die Stockscreener-App
1,033.15
1.93%
-20.31
Schlusskurs vom Vortag:
$1,053.46
Offen:
$1040.31
24-Stunden-Volumen:
125.05K
Relative Volume:
0.37
Marktkapitalisierung:
$64.63B
Einnahmen:
$4.16B
Nettoeinkommen (Verlust:
$1.29B
KGV:
52.76
EPS:
19.5837
Netto-Cashflow:
$734.26M
1W Leistung:
+0.97%
1M Leistung:
+22.34%
6M Leistung:
+37.83%
1J Leistung:
+40.82%
1-Tages-Spanne:
$1,031.19
$1,048.43
1-Wochen-Bereich:
$1,005.78
$1,072.75
52-Wochen-Spanne:
$661.85
$1,072.75
Argen X Se Adr Stock (ARGX) Company Profile
Compare ARGX vs VRTX, REGN, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Argen X Se Adr Stock (ARGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-12-18 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-11-24 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-09-15 | Fortgesetzt | Truist | Buy |
| 2025-09-11 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-08-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-07-08 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-05-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-03-17 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2025-03-12 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2025-01-17 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-11-12 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-11-05 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2024-11-01 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-11-01 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Strong Buy |
| 2024-10-04 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-08-06 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2024-07-25 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-07-23 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-20 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-12-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-07-31 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-07-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-07-17 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-06-15 | Eingeleitet | Societe Generale | Sell |
| 2023-05-31 | Eingeleitet | UBS | Buy |
| 2023-04-25 | Eingeleitet | Citigroup | Buy |
| 2023-03-14 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-12-07 | Eingeleitet | William Blair | Outperform |
| 2022-10-12 | Eingeleitet | Oppenheimer | Perform |
| 2022-07-29 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-06-28 | Fortgesetzt | Stifel | Buy |
| 2022-05-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-29 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-10-29 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-28 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-09-23 | Hochstufung | Redburn | Neutral → Buy |
| 2021-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-23 | Eingeleitet | Deutsche Bank | Hold |
| 2021-07-19 | Fortgesetzt | Wolfe Research | Outperform |
| 2021-06-18 | Eingeleitet | UBS | Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-05-10 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-04-23 | Eingeleitet | Redburn | Neutral |
| 2021-03-05 | Bestätigt | H.C. Wainwright | Neutral |
| 2021-02-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-01-04 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-08-19 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2020-07-29 | Eingeleitet | H.C. Wainwright | Neutral |
| 2020-02-10 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-05 | Eingeleitet | Credit Suisse | Neutral |
| 2019-10-31 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-10-22 | Eingeleitet | JP Morgan | Overweight |
| 2019-09-27 | Eingeleitet | Wells Fargo | Market Perform |
| 2019-09-16 | Fortgesetzt | Cowen | Outperform |
| 2019-06-28 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-01-18 | Fortgesetzt | SunTrust | Buy |
| 2019-01-04 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-12-17 | Eingeleitet | Goldman | Buy |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-06-29 | Eingeleitet | Nomura | Buy |
| 2018-04-09 | Eingeleitet | SunTrust | Buy |
| 2018-01-29 | Bestätigt | JMP Securities | Mkt Outperform |
Alle ansehen
Argen X Se Adr Aktie (ARGX) Neueste Nachrichten
ETFs Investing in argenx SE Sponsored ADR Stocks - TradingView
Resilient Argenx stock climbs after positive myositis data and fresh analyst targets - Ad-hoc-news.de
RBC Capital raises argenx stock price target on myositis data - Investing.com
Strong Argenx stock extends rally after Vyvgart trial win and analyst target hikes. - Ad-hoc-news.de
Gold Gains 1%; NY Empire State Manufacturing Index Rises In August - Sahm
Citizens raises argenx stock price target to $1,200 on trial results - Investing.com
Argenx's Positive Vyvgart Data in Autoimmune Indication Supports Growth and FB102 Broadens Portfolio - Morningstar
Resilient Argenx stock jumps after positive Vyvgart Phase 3 data - Ad-hoc-news.de
TD Cowen raises argenx stock price target to $1,353 on myositis outlook - Investing.com Australia
ARGX Stock Price, Quote & Chart - ChartMill
European ADRs Started The Week Slightly Higher In US Trading - Finimize
There are notable gap-ups and gap-downs in today's session. - ChartMill
H World Group Posts Upbeat Q2 Results, Joins Almonty Industries, Diana Shipping And Other Big Stocks Movi - Benzinga
Argx stock hits all-time high at 954.5 USD By Investing.com - Investing.com Canada
argenx SE (ARGX) Stock Price, News, Quote & History - Yahoo Finance
argenx reports positive Phase 3 ALKIVIA results - grafa.com
Zai Lab, argenx report positive phase 3 data for myositis drug - Investing.com India
Why is Argen-X stock surging today? - Investing.com
Why is Argen-X stock surging today? By Investing.com - Investing.com India
Argenx shares jump after positive Phase 3 results in autoimmune myositis trial - Investing.com South Africa
H World Group Posts Upbeat Q2 Results, Joins Almonty Industries, Diana Shipping And Other Big Stocks Moving Higher On Monday - Sahm
T. Rowe Price (ARGX) discloses 2.68M argenx SE ADRs with 4.3% ownership - Stock Titan
Forte Biosciences earnings on deck as $2.2 billion argenx deal nears - Investing.com
Argenx stock holds near recent highs as half year 2026 update and Forte deal shape outlook - AD HOC NEWS
Weekly Recap: Cash tender offer for Forte and EGM on director appointments - TradingView
Galapagos ADR Representing Ord Shs (LKFT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
argenx launches tender offer for Forte Biosciences at $77 per share - Investing.com
The Charts Reveal Significant Price Movement in Forte Biosciences Stock Ahead of Argenx’s Acquisition Announcement - Barchart.com
Argenx stock price target held at $940 by H.C. Wainwright on acquisition - Investing.com South Africa
Crude Oil Falls Sharply; US Durable Goods Orders Increase 0.3% In June - Benzinga
Baker Hughes Posts Upbeat Q2 Earnings, Joins Forte Biosciences, Eikon Therapeutics And Other Big Stocks M - Benzinga
argenx SE (ARGX) stock price, news, quote and history - Yahoo Finance UK
argenx to buy Forte Biosciences in a deal worth $2.2 billion - grafa.com
Why Forte Biosciences Shares Are Trading Higher By 39%; Here Are 20 Stocks Moving Premarket - Benzinga
Argenx to buy Forte Biosciences for $2.2 billion to expand immunology pipeline - Investing.com UK
Baker Hughes Posts Upbeat Q2 Earnings, Joins Forte Biosciences, Eikon Therapeutics And Other Big Stocks Moving Higher On Monday - Sahm
Weekly Recap: Q2 sales and profit surge and Empasiprubart readout schedule - TradingView
argenx SE Sponsored ADR Revenue Breakdown – DUS:1AEA - TradingView
Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (TEM), Brainsway (BWAY) and Argenx Se (ARGX) - The Globe and Mail
argenx SE ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR - TradingView
RBC Capital raises argenx stock price target to $1,025 on strong Vyvgart sales - Investing.com
H.C. Wainwright reiterates argenx stock rating on strong sales - Investing.com
Guggenheim raises argenx stock price target to $1,185 on strong sales - Investing.com
Citizens cuts argenx stock price target to $932 on valuation - Investing.com
Citizens cuts argenx stock price target to $932 on valuation By Investing.com - Investing.com Canada
Argenx's Robust Vyvgart Growth Drives Margin Expansion as Pipeline Advances - Morningstar
European ADRs Slipped In US Trading Late Thursday - Finimize
argenx Q2 2026 slides: 60% sales growth, seronegative gMG expansion - Investing.com
argenx ADR earnings beat by $0.97, revenue topped estimates - Investing.com
Argenx soars on strong Vyvgart sales, beating estimates By Investing.com - Investing.com Canada
Argenx shares jump on Vyvgart sales beat, pipeline readouts ahead By Investing.com - Investing.com Nigeria
Finanzdaten der Argen X Se Adr-Aktie (ARGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.23%
0.61%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):